other material
confidence high
sentiment positive
materiality 0.80
Vera's atacicept shows 43% placebo-adjusted proteinuria reduction at week 36 in Phase 2b IgAN trial
Vera Therapeutics, Inc.
- Atacicept 150 mg achieved 43% placebo-adjusted UPCR reduction (PP, p=0.003) and 35% (ITT, p=0.012).
- Patients on atacicept had stable eGFR vs. placebo decline; delta 11% (p=0.038), 5.8 mL/min/1.73 m² difference.
- Gd-IgA1 reduced 64% from baseline (p<0.0001); safety consistent with prior studies, low SAE rate (3% vs 9% placebo).
- Phase 3 ORIGIN 3 trial initiated June 2023; topline results expected H1 2025, BLA submission H2 2025.
- Company targets commercial launch in 2026 if atacicept receives FDA approval for IgAN.